Price movement over the last 24 hours
Alcon AG vs Equinix Inc — how do they compare? Alcon AG trades at $66.93 (market cap $32.69B), while Equinix Inc trades at $1,020.48 (market cap $100.89B). The key difference: Equinix Inc is far larger — about 3.1× Alcon AG's market cap, and Equinix Inc pays the higher dividend (1.93%). Which is the better fit depends on your goals.
| ALC | EQIX | |
|---|---|---|
Market Cap | $32.69B | $100.89B |
Sector | Health | Real Estate |
52-Week High | $92.22 | $1.12K |
52-Week Low | $62.02 | $726.09 |
Enterprise Value | $36.28B | $121.17B |
Dividend Yield | 0.54% | 1.93% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Equinix (EQIX) trades at $1,022.93, up 2.09% today, with a bearish technical signal despite recent AI partnership news. The stock shows strong revenue growth to $9.22B in 2025 and a net income margin of 15.07%, but faces high valuation multiples (P/E 69.08) and negative net cash flow. Analyst consensus is strongly bullish with a $1,190 price target, though recent earnings misses and elevated debt levels pose concerns.
Outlook remains mixed: AI infrastructure demand offers growth potential, but high leverage and valuation compression risks weigh on near-term upside. Investors should balance strong institutional support against execution risks and macroeconomic headwinds affecting capital-intensive expansions.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →